Impaired warfarin response secondary to high-dose vitamin K 1 for rapid anticoagulation reversal: Case series and literature review

Pharmacotherapy

Volumn 24, Issue 9, 2004, Pages 1213-1220

  Fugate, Susan E ^a,b   Nichols, Carrie M ^a,c   Cudd, Laura A ^a  

^a Integris Health Anticoagulation Clinics   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c SOUTHWESTERN OKLAHOMA STATE UNIVERSITY   (United States)

Author keywords

Fresh frozen plasma; High dose vitamin K 1; Impaired warfarin response; Urgent anticoagulation reversal; Vitamin K; Warfarin

Indexed keywords

ALPHA TOCOPHEROL; ANTICOAGULANT AGENT; CELECOXIB; CHLORDIAZEPOXIDE; DIGOXIN; ENOXAPARIN; ESTROGEN; FRESH FROZEN PLASMA; GLIBENCLAMIDE; HYDROCHLOROTHIAZIDE; LANSOPRAZOLE; LOW MOLECULAR WEIGHT HEPARIN; MULTIVITAMIN; OMEPRAZOLE; PARACETAMOL; PHYTOMENADIONE; PROGESTERONE; QUINAPRIL; TROGLITAZONE; WARFARIN;

ADULT; ANTICOAGULANT THERAPY; ANTICOAGULATION; ANTICOAGULATION REVERSAL; BLOOD TRANSFUSION; CASE REPORT; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; FEMALE; GASTROESOPHAGEAL REFLUX; GOUT; HEART VALVE REPLACEMENT; HUMAN; HYPERTENSION; IMPAIRED WARFARIN RESPONSE; LUNG EMBOLISM; MALE; PRACTICE GUIDELINE; REVIEW; THROMBOEMBOLISM; URGENT ANTICOAGULATION REVERSAL;

ADULT; ANTICOAGULANTS; ANTIFIBRINOLYTIC AGENTS; DRUG INTERACTIONS; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; VENOUS THROMBOSIS; VITAMIN K; WARFARIN;

EID: 4344656580     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.13.1213.38080     Document Type: Review

References (19)

1. Ansell J, Hirsh J, Dalen J, et al. Managing oral anticoagulant therapy. Chest 2001;119(1 suppl): 22S-38.
2. Naranjo CA, Busto U, Sellers EM, et al. A method of estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
3. Almquist HJ. Vitamin K: discovery identification, synthesis, functions. Fed Proc 1979;38:2687-9.
4. Bentley R, Meganathan R. Biosynthesis of vitamin K (menaquinone) in bacteria. Microbiol Rev 1982;46:241-80.
5. Suttie JW, Jackson CM. Prothrombin structure, activation, and biosynthesis. Physiol Rev 1977;57:1-70.
6. Stenflo J, Fernlund P, Egan W, et al. Vitamin K dependent modifications of glutamic acid residues in prothrombin. Proc Natl Acad Sci U S A 1974;71:2730-3.
7. Whitlon DS, Sadowski JA, Suttie JW. Mechanism of coumarin action: significance of vitamin K epoxide reduction inhibition. Biochemistry 1978;17:1371-7.
8. Stenflo J, Suttie JW. Vitamin K-dependent formation of γ-carboxyglutamic acid. Annu Rev Biochem 1977;46:157-72.
9. Gallop PM, Lian JB, Hauschka PV. Carboxylated calcium-binding proteins and vitamin K. N Engl J Med 1980;302: 1460-6.
10. Wessler S, Gitel SN. Warfarin: from bedside to bench. N Engl J Med 1984;311(10):645-52.
11. Zivelin A, Rao LV, Rapaport SI. Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin K-dependent clotting factors. J Clin Invest 1993;92:2131-40.
12. White RH, McKittrick T, Hutchinson R, Twitchell J. Temporary discontinuation of warfarin therapy: changes in the international normalized ratio. Ann Intern Med 1995;122:40-2.
13. U.S. Department of Health and Human Services, National Institutes of Health. Fresh frozen plasma: indications and risks. National Institutes of Health consensus statement, September 24-26, 1984. Available from http://odp.od.nih.gov/consensus/cons/045/045_statement.htm. Accessed April 27, 2004.
14. Anonymous. Practice parameter for the use of fresh-frozen plasma, cryoprecipitate, and platelets. JAMA 1994;271(10): 777-81.
15. Anonymous. Practice guidelines for blood component therapy: a report by the American society of anesthesiologist task force on blood component therapy. Anesthesiology 1996;84(3): 732-47.
16. Grafstein E, Innes G. Guidelines for red blood cell and plasma transfusion for adults and children: an emergency physician's overview of the 1997 Canadian blood transfusion guidelines part 2: plasma transfusion and infectious risk. J Emerg Med 1998;16(2):239-41.
17. Cartmill M, Dolan G, Byrne JL, Byrne PO. Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergencies. Br J Neurosurg 2000;14(5):458-61.
18. Hellstern P, Muntean W, Schramm W, et al. Practical guidelines for the clinical use of plasma. Thromb Res 2002;107:S53-7.
19. Boulis NM, Bobek MP, Schmaler A, Hoff JT. Use of factor IX complex in warfarin-related intracranial hemorrhage. Neurosurgery 1999;45:1113-18.